{"filing":{"accession_number":"0001104659-26-104106","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-31","primary_document":"tm2624539d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926104106/tm2624539d1_8k.htm"},"events":[{"id":30766,"run_id":28205,"accession_number":"0001104659-26-104106","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"BioXcel entered into a Super-Priority Senior Secured Priming Debtor-in-Possession Credit Agreement on August 31, 2026, creating a new direct financial obligation of up to $77.25 million in DIP financing to provide critical liquidity for the company's operations during its Chapter 11 bankruptcy proceedings.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33472,"accession_number":"0001104659-26-104106","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"BioXcel entered into a Super-Priority Senior Secured Priming Debtor-in-Possession Credit Agreement on August 31, 2026, creating a new direct financial obligation of up to $77.25 million in DIP financing. While the company is in Chapter 11 bankruptcy (filed August 27, 2026), the DIP facility itself represents a new debt obligation disclosed under Item 2.03. This is material as it provides critical liquidity for the company's operations during bankruptcy proceedings.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:02:02.247949+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30767,"run_id":28205,"accession_number":"0001104659-26-104106","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"BioXcel was notified by Nasdaq on August 31, 2026, that its common stock would be delisted in accordance with Nasdaq Listing Rules as a result of the Company's Chapter 11 bankruptcy filing on August 27, 2026, with trading to be suspended on September 8, 2026, and the stock expected to move to the OTC Pink Limited Market.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33473,"accession_number":"0001104659-26-104106","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"BioXcel was notified by Nasdaq on August 31, 2026, that its common stock would be delisted in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM 5101-1 as a result of the Company's Chapter 11 bankruptcy filing on August 27, 2026. Trading will be suspended on September 8, 2026, and the stock is expected to move to the OTC Pink Limited Market, a significantly less liquid venue. This is a definitive delisting notice, not merely a risk or warning, making it a material event that directly affects the registrant's public market status and shareholder liquidity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:02:02.247949+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33472,"accession_number":"0001104659-26-104106","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"BioXcel entered into a Super-Priority Senior Secured Priming Debtor-in-Possession Credit Agreement on August 31, 2026, creating a new direct financial obligation of up to $77.25 million in DIP financing. While the company is in Chapter 11 bankruptcy (filed August 27, 2026), the DIP facility itself represents a new debt obligation disclosed under Item 2.03. This is material as it provides critical liquidity for the company's operations during bankruptcy proceedings.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:02:02.247949+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-09-01"},{"id":33473,"accession_number":"0001104659-26-104106","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"BioXcel was notified by Nasdaq on August 31, 2026, that its common stock would be delisted in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM 5101-1 as a result of the Company's Chapter 11 bankruptcy filing on August 27, 2026. Trading will be suspended on September 8, 2026, and the stock is expected to move to the OTC Pink Limited Market, a significantly less liquid venue. This is a definitive delisting notice, not merely a risk or warning, making it a material event that directly affects the registrant's public market status and shareholder liquidity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:02:02.247949+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-09-01"}]}